Back To Search Results


Editor: Said Hajouli Updated: 6/5/2023 9:33:23 PM


Arrhythmia is an abnormal rhythm of the heart. The only normal rhythm of the heart is a normal sinus rhythm. In this rhythm, an impulse is generated in the sinoatrial (SA) node, which is conducted through and slowed down while passing through the atrioventricular node (AV). It is then conducted through the bundle of His, to the left and right bundle branches, and eventually into the Purkinje fibers. Any deviation from this conduction pathway results in arrhythmia. Arrhythmias can be classified based on various criteria. The most common way to categorize them is based on the rate of conduction as bradyarrhythmia with a heart rate of fewer than 60 beats per minute (bpm) and tachyarrhythmia with a heart rate higher than 100 bpm.

Clinical Significance

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Clinical Significance

The prevalence of arrhythmias is expected to be 1.5% to 5% in the general population, with atrial fibrillation being the most common.[1] Arrhythmias may or may not produce any symptoms and can be paroxysmal, leading to difficulty in estimating true prevalence. The overall presence of arrhythmia is associated with higher morbidity and mortality. 

Evaluation of Arrhythmia

In patients suspected of arrhythmias, an electrocardiogram (EKG) is the first step and will usually give the diagnosis. However, at times, the patient may suffer from paroxysmal arrhythmia. The following modalities can be used for diagnosing based on the frequency of the symptoms a patient has secondary to a suspected arrhythmia.

  • Ambulatory EKG monitoring for patients with frequent symptoms
  • The event recorder needs to be triggered by the patient to record and will not a viable choice for patients with syncope.
  • Loop event recorder records up to 2 minutes before the trigger. It is good for patients with syncope.
  • Implantable loop recorder for patients with less frequent symptoms. 


Tachyarrhythmia is defined as an abnormal rhythm with a ventricular heart rate of 100 beats per minute or more. It can be further classified based on the origin of the arrhythmia into:

Supraventricular Tachycardia (SVT): Arrhythmia originating from above the AV node (from atrial origin or AV junction origin). 

  • Atrial fibrillation (AFib)
  • Atrial flutter
  • Atrial tachycardia
  • Atrial premature complex (PAC)
  • Atrioventricular nodal reentrant tachycardia (AVNRT)
  • Atrioventricular reentrant tachycardia (AVRT)
  • AV junctional extrasystoles

Ventricular Tachycardia (VT): The origin of the arrhythmia is below the AV node.

  • Ventricular fibrillation (V-fib)
  • Ventricular premature beats (PVC)
  • Ventricular tachycardia (sustained or non-sustained) 

Tachyarrhythmias can also be classified based on the QRS complex duration into:

Narrow QRS complex tachycardia when QRS is <120 milliseconds in duration:

  • Sinus tachycardia
  • Atrial tachycardia (AT)
  • Atrial flutter
  • Atrioventricular nodal reentrant tachycardia (AVNRT)
  • Atrioventricular reentrant tachycardia (AVRT)
  • Junctional ectopic tachycardia
  • Sinoatrial nodal reentrant tachycardia (SANRT)
  • Atrial fibrillation (irregular QRS complexes)

Wide QRS complex tachycardia (QRS ≥120 milliseconds in duration) is classified as monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, or ventricular fibrillation.

Supraventricular Tachycardia Syndromes[2][3]

These are usually narrow complex tachycardias with QRS width being less than 3 mm or 120 milliseconds on the EKG strip. Supraventricular tachycardia is further classified into atrioventricular reciprocating tachycardia, atrioventricular nodal reentrant tachycardia, and atrial tachycardia based on the mechanism of tachycardia. 

      I. Atrioventricular reciprocating tachycardia (AVRT): As found in Wolff-Parkinson-White syndrome (the presence of delta wave without arrhythmia doesn’t require investigation or treatment).

Mechanism: Accessory pathway present outside of the AV node-Bundle of Kent. It can be further categorized into:

  • Antidromic: Conduction down the accessory pathway and up to the AV node leading to the formation of a delta wave.
  • OrthodromicConduction down the AV node into an accessory pathway with no delta wave.

Signs & Symptoms: Palpitation, shortness of breath, or syncope.

EKG Findings: Slurred upstroke of the QRS, delta wave, may give an impression of the wide QRS complex.

Management: Amiodarone or procainamide. If this fails, the next step is synchronized cardioversion.

Definitive Therapy: Ablation of the accessory pathway.

      II. Atrioventricular Nodal Reentrant Tachycardia (AVNRT)

Mechanism: Slow & fast fibers present in AV node & peri-nodal tissue leading to re-entry.

Signs & Symptoms: Sudden tachycardia, palpitation, shortness of breath, chest tightness, or syncope.

EKG Findings: Narrow complex tachycardia with P waves hidden in T waves. Heart rate is in the range of 150-160 bpm.


Step 1: Carotid massage/Valsalva maneuver 

Step 2: Adenosine

Step 3: Cardioversion

Step 4: Ablation or chronic suppressive therapy with beta-blockers and calcium channel blockers such as diltiazem/verapamil.

      III. Atrial fibrillation: It is the most common arrhythmia in the United States. It affects more than 20% of the general population at some time in their lives.[4] There are five types based on their duration:[5]

  • New-onset
  • Paroxysmal: Self-terminating or intermittent
  • Persistent: Fails to self-terminate within 7 days and requires treatments (medical or electrical cardioversion) 
  • Long-standing Persistent: Lasts for ≥ 1 year
  • Permanent: Persistent for ≥ 1 year despite treatment

Mechanism: Multiple reentrant wavelets due to atrial ectopy from muscle fibers near the proximal part of the pulmonary vein.

Signs & Symptoms: It can be asymptomatic or can cause symptoms like palpitation, shortness of breath, irregularly irregular pulse, or even hypotension.

EKG Findings: Irregularly irregular narrow complex tachycardia with no discernable P-waves.

Management: The management strategy for atrial fibrillation can be classified into rate control or rhythm control. The decision to use a rate control or a rhythm-control strategy depends on the hemodynamic stability, candidacy for ablation, and the presence of co-morbidities. Patients with atrial fibrillation are at increased risk of ischemic-embolic stroke, and anticoagulation recommendations are based on the CHA2DS2VaSc score.

The CHA2DS2VaSc score is determined by the presence of the following factors: Congestive heart failure (CHF) with ejection fraction (EF) less than 40%, hypertension, age > 65 years, diabetes mellitus, history of stroke (non-hemorrhagic), or transient ischemic attack (TIA), vascular disease (peripheral vascular disease - PVD), age > 75 years, female sex. Each factor adds a point to the score, except for a history of stroke/TIA, which adds 2 points. 

  • If the score is 0: No anticoagulation or aspirin based on individual assessment
  • If the score is 1: Aspirin or anticoagulation based on individual assessment.
  • If the score is 2 or more: Anticoagulation is recommended if not at high risk of bleeding. 

Rate Control Strategy: The heart rate goal is < 110 bpm in patients with chronic atrial fibrillation. It can be achieved with either beta-blockers or calcium channel blockers. Digoxin is usually used as adjuvant therapy in a patient with a "difficult to control" heart rate or in heart failure patients.

Cardioversion Strategy: Cardioversion is preferred in hemodynamically unstable patients or if rate control fails. It is also preferred in a young patient with no other co-morbidities. Cardioversion can be performed within 36 hrs of the onset of atrial fibrillation, but if the presentation is delayed or is of unknown duration, the absence of thrombi needs to be confirmed with a transesophageal echocardiogram (TEE). If a thrombus is present on an echocardiogram, the patient will need anticoagulation for at least three weeks before cardioversion can be performed. The patient needs to be on anticoagulation for at least four weeks post cardioversion. Various modalities are available for cardioversion therapy and include synchronized electric cardioversion or chemical cardioversion with medications including flecainide, propafenone, amiodarone, or dronedarone. Maze procedure is usually reserved for the patient undergoing other cardiac surgery.

  • Atrial Flutter[6]

Mechanism: Reentrant circuit usually around the tricuspid annulus in the right atrium.

Signs & Symptoms: Can be asymptomatic, or it can cause palpitation, shortness of breath, or hypotension.

EKG Findings: Regular tachycardia with Saw-tooth appearance of P wave with a variable degree of AV block.

Management: General goals include control of ventricular rate with AV blocking agents (beta-blockers or calcium channel blockers), but the restoration of sinus rhythm through cardioversion or ablation is preferred.  

  •  Multifocal Atrial Tachycardia (MAT)

Mechanism: multiple automatic atrial foci due to increased sympathetic tone secondary to various causes, including hypoxemia (chronic obstructive pulmonary disease (COPD), or stimulant use.

Signs & Symptoms: Usually asymptomatic. Patients will have symptoms of the underlying illness, such as dyspnea.

EKG Findings: Three or more P wave morphologies with different PR intervals.

Management: Oxygen therapy if hypoxemic and treatment of the underlying cause.

Refractory cases: Rate Control with calcium channel blockers as the first choice in the setting of COPD followed by beta-blockers.

  • Junctional tachycardia:[7] Arrhythmia originating from or near the AV node.

Mechanism: Rhythm arising from the AV node.

Risk Factors: Post cardiac surgery, myocardial ischemia (or during reperfusion), or digoxin toxicity.

Signs & Symptoms: Usually well-tolerated and asymptomatic.

EKG Findings: Inverted P Wave in the lead 2 with short PR or No P waves with a narrow complex.

Management: Treat the underlying cause. 

     IV. Ventricular Tachycardia: Origin is below the AV node. It is the major cause of sudden cardiac deaths in the United States.

a) Non-Sustained Ventricular Tachycardia:[8] When the rapid ventricular rhythm terminates on its own within 30 seconds.

Mechanism: Channelopathies secondary to structural abnormality, electrolyte disturbances, metabolic imbalance, and the effect of pro-arrhythmic drugs.

Risk Factors: Structural or ischemic heart disease.

Signs & Symptoms: Asymptomatic or palpitations.

EKG Findings: Monomorphic wide complex with more than three beats in a row but lasts less than three seconds.

Management: Implantable cardioverter-defibrillator (ICD) and/or medical therapy.

b) Sustained Ventricular Tachycardia

Mechanism: Presence of damaged fibers in ischemic heart disease leading to re-entry of current. Some patients do not have structural heart disease. Approximately 10% of the cases are idiopathic.

Risk Factors: Structural heart disease and post-myocardial infarction.

Signs & Symptoms: Palpitation, hypotension, or syncope.

EKG Findings: Monomorphic wide complex tachycardia.

Management: Intravenous lidocaine, amiodarone, or procainamide. Catheter ablation is an option too.

c) Ventricular Fibrillation

Mechanism: Presence of damaged fibers in ischemic heart disease leading to re-entry of current leading to disorganized high-frequency excitation. Patients with Cardiomyopathies can have Ventricular fibrillation due to an increase in end-diastolic pressure, wall tension, or the presence of abnormal channels in ventricular fibers.

Risk Factors: Structural heart disease and post-myocardial infarction.

Signs & Symptoms: Syncope and death if not treated immediately.

EKG Findings: Polymorphic fibrillatory waves.

Management: Unsynchronized cardioversion followed by amiodarone.

d) Torsades De Pointes:

Mechanism: It is usually precipitated by premature ventricular contraction leading to the “R on T phenomenon.”

Risk Factors: Congenital long QTc with hypokalemia and hypomagnesemia.

Signs & Symptoms: Syncope and death if not treated immediately.

EKG Findings: Polymorphic wide-complex tachycardia with a heart rate > 300 bpm.

Management: Intravenous magnesium or Isoproterenol, which increases heart rate and decreases QT-duration. Avoid hypokalemia and hypomagnesemia. Chronic therapy with beta-blockers in patients with long QT syndrome.

Bradyarrhythmias:[9][10] Bradyarrhythmia is defined as a heart rate below 60 beats per minute (bpm) and comprises several rhythm disorders, including atrioventricular (A-V) blocks and sinus node disorders.

Sinus Bradycardia

Mechanism: Increased vagal tone. It can be physiological in athletes.

Signs & Symptoms: Usually asymptomatic. It can lead to orthostasis or dizziness if pathological.

EKG Findings: Sinus rhythm with an upright P wave in lead II and biphasic in V1.

Management: No treatment is required unless pathological with an inadequate heart rate increase with leg raise test. Treat with isoproterenol or pacemaker if no relief. 

Atrioventricular Blocks

Mechanism: Atrial impulses are conducted with a delay or not at all when an electrical impulse reaches a tissue that not excitable or is in a refractory period.

a) First Degree AV Block: Caused by increased vagal tone or conduction impairment or due to medications.

Signs & Symptoms: Generally asymptomatic but can cause dizziness.

EKG Findings: PR interval is greater than 200 milliseconds.

Management: Usually, no need to treat.

 b) Second Degree AV Block: Further classified into Mobitz I block, where there is a progressive prolongation of the PR interval followed by a skipped beat, and Mobitz II block, where there is a randomly dropped QRS complex on an EKG.

Sign & Symptoms: Can be asymptomatic, dizziness, palpitations, weakness, syncope.

EKG Findings: Mobitz type I shows progressive prolongation of the PR interval followed by a dropped QRS complex or dropped beat. Mobitz type II has randomly dropped QRS complexes.

Management: Pacemaker is indicated in symptomatic Mobitz I and all of Mobitz II heart block.

 c) Third Degree or complete AV Block

Mechanism: Lack of conduction of atrial impulse to ventricle leading to independent contractions.

Sign & Symptoms: Profound bradycardia, hypotension, and can lead to asystole and cardiac arrest.

EKG Findings: Bradycardia, P waves occur independently of QRS and Wide QRS for ventricular rhythm.

Management: Pacemaker placement.

Sinus Node Dysfunction

Mechanism: Senescence of the SA node, an ischemic event involving the SA node leading to impulse generation at a slower rate.

a) Sinus Pause: When the SA node has delayed impulse generation.

b) Sinus Arrest: Failure of impulse generation.

c) SA Nodal Exit Block: Failure of impulse transmission.

Sign & Symptoms: Bradycardia, dizziness, palpitation, or syncope.

EKG Findings: P wave not originating at a determined rate with regularity

Management: Symptomatic patients require pacemaker placement.

Other Issues

Hypertrophic Obstructive Cardiomyopathy

Mechanism: Subaortic outflow tract obstruction from abnormal hypertrophy of the septal region of the heart, leading to precipitation of ventricular arrhythmias.

Risk Factor: Autosomal dominant mutation in the gene coding for cardiac sarcomere(Beta myosin heavy chain). Suspect this in a patient with a family history of sudden cardiac death in 2 first-degree relatives.

Symptoms: Syncope with exertion, palpitation, develops early heart failure symptoms. 

Treatment: Beta-blockers are the mainstay of therapy. Surgery is indicated for patients with obstructive physiology with an outflow gradient greater than 50 mmHg. The defibrillator is indicated for patients who are symptomatic post maximal medical therapy, abnormal systolic blood pressure response to exercise, septal thickness > 30 mm, runs of ventricular tachycardia, or ventricular fibrillation on telemetry or during the stress test.

Indications for ICD placements to prevent sudden cardiac death with arrhythmia:

  • CHF with EF < 35% after three months of maximal medical therapy.
  • Myocardial infarction (MI) with EF < 40% with inducible VT or VF in electrophysiological studies.
  • MI with EF < 30%
  • Patients with long QT if QTc > 500 and an episode of unexplained syncope or Holter showing NSVTs

Enhancing Healthcare Team Outcomes

Arrhythmias can pose a diagnostic dilemma. The patient presentation can be varied even for the same arrhythmia and can require a different management approach based on the patient's clinical condition and characteristics. While clinical history, physical exam, and EKG findings may reveal particular kinds of arrhythmia, it can sometimes be challenging to form an appropriate management plan without an expert opinion. While an internist is always involved in the care of patients with arrhythmia, it is essential to consult an interprofessional team of specialists, including cardiologists, electrophysiologists, and interventionists.

Based on the condition, the patient may need further evaluation with electrophysiological or ischemia workup for the cause of arrhythmia, which will eventually be treated by a cardiac catheterization or ablation procedure. The nurses are vital members of the interprofessional group as they will monitor the patient's vital signs, telemetry, and assist with the patient and family's education. It has been shown that hospitals with a dedicated arrhythmia team consisting of a nurse, electrophysiologist, noninvasive arrhythmia expert, and internist have shown significant improvement in the outcomes of patients.[11]


(Click Image to Enlarge)
A graphical representation of the Electrical conduction system of the heart showing the Sinoatrial node, Atrioventricular nod
A graphical representation of the Electrical conduction system of the heart showing the Sinoatrial node, Atrioventricular node, Bundle of His, Purkinje fibers, and Bachmann's bundle
Contributed by Wikimedia Commons (Public Domain)



Lakshminarayan K, Anderson DC, Herzog CA, Qureshi AI. Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States. The neurologist. 2008 May:14(3):143-50. doi: 10.1097/NRL.0b013e31815cffae. Epub     [PubMed PMID: 18469671]


Kaplan J, Lala V. Paroxysmal Atrial Tachycardia. StatPearls. 2023 Jan:():     [PubMed PMID: 30855901]


Hafeez Y, Quintanilla Rodriguez BS, Ahmed I, Grossman SA. Paroxysmal Supraventricular Tachycardia. StatPearls. 2023 Jan:():     [PubMed PMID: 29939521]


Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. European heart journal. 2006 Apr:27(8):949-53     [PubMed PMID: 16527828]

Level 2 (mid-level) evidence


Schmidt C, Kisselbach J, Schweizer PA, Katus HA, Thomas D. The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation. Vascular health and risk management. 2011:7():193-202. doi: 10.2147/VHRM.S10758. Epub 2011 Mar 31     [PubMed PMID: 21490945]

Level 3 (low-level) evidence


Rodriguez Ziccardi M, Goyal A, Maani CV. Atrial Flutter. StatPearls. 2023 Jan:():     [PubMed PMID: 31082029]


Cundiff NM, Robinson JA, Cannon BC, Snyder CS. Atrioventricular junctional tachycardia with exit block in an adolescent. HeartRhythm case reports. 2018 Dec:4(12):594-597. doi: 10.1016/j.hrcr.2018.07.019. Epub 2018 Sep 21     [PubMed PMID: 30581740]

Level 3 (low-level) evidence


Allen SM, Abrich VA, Bibby PS, Fishman D, Shen WK, Sorajja D. Prevalence and Prognostic Significance of Nonsustained Ventricular Tachycardia in Patients With a Left Ventricular Ejection Fraction from 35% to 50. The American journal of cardiology. 2018 Feb 1:121(3):330-335. doi: 10.1016/j.amjcard.2017.10.023. Epub 2017 Oct 31     [PubMed PMID: 29224709]


Kerola T, Eranti A, Aro AL, Haukilahti MA, Holkeri A, Junttila MJ, Kenttä TV, Rissanen H, Vittinghoff E, Knekt P, Heliövaara M, Huikuri HV, Marcus GM. Risk Factors Associated With Atrioventricular Block. JAMA network open. 2019 May 3:2(5):e194176. doi: 10.1001/jamanetworkopen.2019.4176. Epub 2019 May 3     [PubMed PMID: 31125096]


Leonelli FM, De Ponti R, Bagliani G. Challenges in Bradicardias Interpretation. Cardiac electrophysiology clinics. 2019 Jun:11(2):261-281. doi: 10.1016/j.ccep.2019.02.002. Epub 2019 Apr 12     [PubMed PMID: 31084850]


Stewart S, Ball J, Horowitz JD, Marwick TH, Mahadevan G, Wong C, Abhayaratna WP, Chan YK, Esterman A, Thompson DR, Scuffham PA, Carrington MJ. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet (London, England). 2015 Feb 28:385(9970):775-84. doi: 10.1016/S0140-6736(14)61992-9. Epub 2014 Nov 17     [PubMed PMID: 25467562]

Level 2 (mid-level) evidence